Ameritas Investment Partners’s C4 Therapeutics CCCC Stock Holding History

Ameritas Investment Partners’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43K	Buy	+9,198	New	+$31.5K	﹤0.01%	2339
2025 Q2	–	Sell	-5,744	Closed	-$9.19K	–	3222
2025 Q1	$9.19K	Hold	5,744	–	–	﹤0.01%	2849
2024 Q4	$20.7K	Hold	5,744	–	–	﹤0.01%	2620
2024 Q3	$32.7K	Hold	5,744	–	–	﹤0.01%	2413
2024 Q2	$26.5K	Buy	+5,744	New	+$34.3K	﹤0.01%	2491
2023 Q2	–	Sell	-2,962	Closed	-$9.3K	–	3128
2023 Q1	$9.3K	Hold	2,962	–	–	﹤0.01%	2749
2022 Q4	$24.4K	Hold	2,962	–	–	﹤0.01%	2480
2022 Q3	$25K	Hold	2,962	–	–	﹤0.01%	2402
2022 Q2	$22K	Hold	2,962	–	–	﹤0.01%	2503
2022 Q1	$72K	Hold	2,962	–	–	﹤0.01%	1838
2021 Q4	$95K	Hold	2,962	–	–	﹤0.01%	1709
2021 Q3	$132K	Buy	2,962 +262	+10%	+$11.2K	﹤0.01%	1514
2021 Q2	$102K	Buy	2,700 +1,806	+202%	+$64.7K	﹤0.01%	1708
2021 Q1	$33K	Hold	894	–	–	﹤0.01%	2314
2020 Q4	$30K	Buy	+894	New	+$25.9K	﹤0.01%	2272

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ameritas Investment Partners's CCCC Position: Q2 2026 in Review

Ameritas Investment Partners opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 9,198 shares worth $43K. The stake represents ﹤0.01% of the portfolio and ranks #2339 among its holdings. This is a return to the name: Ameritas Investment Partners previously reported a position in CCCC as recently as Q1 2025.

Ameritas Investment Partners first reported a position in CCCC in Q4 2020 and has held it in 15 quarters since. The position peaked at $132K in Q3 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Ameritas Investment Partners held 9,198 shares of C4 Therapeutics worth $43K as of Q2 2026.
C4 Therapeutics was a new Ameritas Investment Partners position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2339 holding.
Ameritas Investment Partners first reported a position in C4 Therapeutics in Q4 2020 and has held it in 15 quarters since.
Ameritas Investment Partners's C4 Therapeutics position peaked at $132K in Q3 2021.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.